CO2024003401A2 - Compuestos de pirazolo[3,4-b]piridina para el tratamiento de enfermedades autoinmunitarias - Google Patents
Compuestos de pirazolo[3,4-b]piridina para el tratamiento de enfermedades autoinmunitariasInfo
- Publication number
- CO2024003401A2 CO2024003401A2 CONC2024/0003401A CO2024003401A CO2024003401A2 CO 2024003401 A2 CO2024003401 A2 CO 2024003401A2 CO 2024003401 A CO2024003401 A CO 2024003401A CO 2024003401 A2 CO2024003401 A2 CO 2024003401A2
- Authority
- CO
- Colombia
- Prior art keywords
- pyrazolo
- treatment
- autoimmune diseases
- pyridine compounds
- compounds
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 150000005230 pyrazolo[3,4-b]pyridines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021120406 | 2021-09-24 | ||
| CN2022089033 | 2022-04-25 | ||
| PCT/EP2022/076306 WO2023046806A1 (en) | 2021-09-24 | 2022-09-22 | Pyrazolo[3,4-b]pyridine compounds for the treatment of autoimmune disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024003401A2 true CO2024003401A2 (es) | 2024-04-29 |
Family
ID=83688579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0003401A CO2024003401A2 (es) | 2021-09-24 | 2024-03-19 | Compuestos de pirazolo[3,4-b]piridina para el tratamiento de enfermedades autoinmunitarias |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240360126A1 (enExample) |
| EP (1) | EP4405051A1 (enExample) |
| JP (1) | JP2024534567A (enExample) |
| KR (1) | KR20240065092A (enExample) |
| CN (1) | CN118076604A (enExample) |
| AR (1) | AR127126A1 (enExample) |
| AU (1) | AU2022351495A1 (enExample) |
| CA (1) | CA3228485A1 (enExample) |
| CL (1) | CL2024000791A1 (enExample) |
| CO (1) | CO2024003401A2 (enExample) |
| CR (1) | CR20240134A (enExample) |
| IL (1) | IL310443A (enExample) |
| MX (1) | MX2024003444A (enExample) |
| PE (2) | PE20240815A1 (enExample) |
| TW (1) | TW202328129A (enExample) |
| WO (1) | WO2023046806A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024222889A1 (zh) * | 2023-04-28 | 2024-10-31 | 成都思倍博医药科技有限公司 | 含氧代吡啶并脂肪环或脂杂环结构的化合物及其医药用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3080124A1 (en) * | 2013-12-13 | 2016-10-19 | Takeda Pharmaceutical Company Limited | Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors |
| CR20190119A (es) | 2016-09-09 | 2019-06-03 | Novartis Ag | Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje |
| JP7407740B2 (ja) | 2018-05-18 | 2024-01-04 | ノバルティス アーゲー | Ｔｌｒ７／ｔｌｒ８阻害剤の結晶形態 |
| WO2022013136A1 (en) * | 2020-07-14 | 2022-01-20 | F. Hoffmann-La Roche Ag | Hydroisoquinoline or hydronaphthyridine compounds for the treatment of autoimmune disease |
-
2022
- 2022-09-22 AU AU2022351495A patent/AU2022351495A1/en active Pending
- 2022-09-22 CN CN202280063841.XA patent/CN118076604A/zh active Pending
- 2022-09-22 CA CA3228485A patent/CA3228485A1/en active Pending
- 2022-09-22 IL IL310443A patent/IL310443A/en unknown
- 2022-09-22 MX MX2024003444A patent/MX2024003444A/es unknown
- 2022-09-22 AR ARP220102558A patent/AR127126A1/es unknown
- 2022-09-22 JP JP2024518351A patent/JP2024534567A/ja active Pending
- 2022-09-22 PE PE2024000482A patent/PE20240815A1/es unknown
- 2022-09-22 EP EP22786353.7A patent/EP4405051A1/en active Pending
- 2022-09-22 KR KR1020247009335A patent/KR20240065092A/ko active Pending
- 2022-09-22 WO PCT/EP2022/076306 patent/WO2023046806A1/en not_active Ceased
- 2022-09-22 PE PE2024003046A patent/PE20250401A1/es unknown
- 2022-09-22 CR CR20240134A patent/CR20240134A/es unknown
- 2022-09-23 TW TW111136043A patent/TW202328129A/zh unknown
-
2024
- 2024-03-15 US US18/606,123 patent/US20240360126A1/en active Pending
- 2024-03-18 CL CL2024000791A patent/CL2024000791A1/es unknown
- 2024-03-19 CO CONC2024/0003401A patent/CO2024003401A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240360126A1 (en) | 2024-10-31 |
| CN118076604A (zh) | 2024-05-24 |
| CL2024000791A1 (es) | 2024-09-06 |
| AU2022351495A1 (en) | 2024-02-01 |
| EP4405051A1 (en) | 2024-07-31 |
| IL310443A (en) | 2024-03-01 |
| WO2023046806A1 (en) | 2023-03-30 |
| MX2024003444A (es) | 2024-04-03 |
| PE20250401A1 (es) | 2025-02-11 |
| AR127126A1 (es) | 2023-12-20 |
| CR20240134A (es) | 2024-05-07 |
| JP2024534567A (ja) | 2024-09-20 |
| CA3228485A1 (en) | 2023-03-30 |
| PE20240815A1 (es) | 2024-04-18 |
| KR20240065092A (ko) | 2024-05-14 |
| TW202328129A (zh) | 2023-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2025010435A2 (es) | Compuestos tricíclicos para el tratamiento de cáncer | |
| CL2021002621A1 (es) | Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria | |
| DOP2022000039A (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| AR126854A1 (es) | Compuestos macrocíclicos para el tratamiento de cáncer | |
| ECSP22050936A (es) | Compuestos tric?clicos sustituidos | |
| CL2021002883A1 (es) | Moduladores de thr-ß y métodos de uso de estos | |
| CO2022001094A2 (es) | Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas | |
| MX2021005754A (es) | Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento de cancer. | |
| AR133266A1 (es) | Macrociclos para el tratamiento de enfermedades autoinmunitarias | |
| AR133199A1 (es) | Macrociclos bicíclicos para el tratamiento de enfermedades autoinmunitarias | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| CL2022000032A1 (es) | Derivados de imidazo[4,5-c]piridina como agonistas de los receptores tipo toll | |
| UY39181A (es) | COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO | |
| CL2019001023A1 (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia. | |
| MX2020007443A (es) | Derivados de 2,4,6,7-tetrahidro-pirazolo[4,3-d]pirimidin-5-ona y compuestos relacionados como moduladores del receptor c5a para el tratamiento de vasculitis y enfermedades inflamatorias. | |
| UY31588A1 (es) | Derivados de imidazo[1,2-a]piridin-2-carboxamidas, su preparacion y su aplicacion en terapéutica | |
| CO2024003401A2 (es) | Compuestos de pirazolo[3,4-b]piridina para el tratamiento de enfermedades autoinmunitarias | |
| CO2024000083A2 (es) | Pirrolo[2,3-d]pirimidinas sustituidas, su preparación y su aplicación terapéutica | |
| CO2022006942A2 (es) | Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria | |
| AR133167A1 (es) | Macrociclos para el tratamiento de enfermedad autoinmunitaria | |
| DOP2024000096A (es) | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno | |
| UY31593A1 (es) | Derivados de 2-heteroaroil-imidazo[1,2-a]piridina, su preparacion y su aplicacion en terapéutica | |
| AR131849A1 (es) | Compuestos tricíclicos para el tratamiento de cáncer | |
| AR133915A1 (es) | Macrociclos para el tratamiento de enfermedades autoinmunitarias | |
| AR131945A1 (es) | Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno |